Trevi Therapeutics (TRVI) Short term Debt (2021 - 2023)

Trevi Therapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $7.5 million for Q1 2023.

• In Q1 2023, Short term Debt rose 6.89% year-over-year to $7.5 million; the TTM figure through Mar 2023 stood at $7.5 million (up 6.89% YoY), while the FY2022 annual figure was $7.0 million, up 20.01% from the prior year.
• Short term Debt for Q1 2023 stood at $7.5 million, up from $7.0 million in the prior quarter.
• The five-year high for Short term Debt was $7.5 million in Q1 2023, with the low at $583000.0 in Q1 2021.
• The 3-year median for Short term Debt is $7.0 million (2022), against an average of $5.4 million.
• The sharpest annual moves came in 2022 and 2023: Short term Debt jumped 1100.69% in 2022, then grew 6.89% in 2023.
• Trevi Therapeutics' Short term Debt stood at $5.8 million in 2021, then advanced by 20.01% to $7.0 million in 2022, then grew by 6.89% to $7.5 million in 2023.
• Business Quant data shows TRVI's Short term Debt at $7.5 million in Q1 2023, $7.0 million in Q4 2022, and $7.0 million in Q3 2022.